The Role of Recombinant Secretory Leukocyte Protease Inhibitor to CD163, FGF-2, IL-1 and IL-6 Expression in Skin Wound Healing
DOI: https://doi.org/10.2147/CCID.S358897
2022-05-18
Abstract:Elly Munadziroh, 1 Giovani Anggasta Putri, 2 Vera Ristiana, 2 Titien Hary Agustantina, 1 Intan Nirwana, 1 Fathilah Abdul Razak, 1, 3 Meircurius Dwi Condro Surboyo 4 1 Department of Dental Materials, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia; 2 Bachelor of Dental Sciences, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia; 3 Department of Oral and Craniofacial Sciences, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, 50603, Malaysia; 4 Department of Oral Medicine, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia Correspondence: Elly Munadziroh, Department of Dental Materials, Faculty of Dental Medicine, Universitas Airlangga, Jalan Prof. Dr. Moestopo No. 47, Surabaya, 60132, Indonesia, Tel +6231-5030255, Email Background: The wound healing process can be optimized through the addition of a biomaterial such as recombinant secretory leukocyte protease inhibitor (rSLPI). The SLPI is a non-glycosylated proteomic material that inhibits protease enzymes and has anti-inflammatory properties, thus accelerating wound healing. This study analyzed the administration of rSLPI doses 0.04 cc and 0.06 cc in skin wound healing on the CD163 expression of macrophages and cytokines such as interleukin 1 (IL-1), interleukin 6 (IL-6) and fibroblast growth factor 2 (FGF-2). Materials and Methods: rSLPI produced from Escherichia coli TOP10 as the cloning host, BL21 (DE3) strains as the expression host and pET30a plasmids were used for the expression system construction. The wound was created on Wistar rat dorsal skin, then rSLPI 0.04 cc and 0.06 cc was administered. In the next four days, the back skin was biopsied and stained by immunohistochemistry to analyze the CD163, FGF-2, IL-1 and IL-6 expression. Results: The administration of rSLPI increased CD163 and FGF-2 expression dependent on dose (p< 0.05). On the other hand, administration of rSLPI decreased IL-1 and IL-6 expression depending on dose (p < 0.05). Conclusion: The administration of rSLPI is able to accelerate the wound healing process by increasing the CD163 and FGF-2 expression. The cytokines such as IL-1 and IL-6 decreased depending on rSLPI doses. Keywords: recombinant secretory leukocyte protease inhibitor, wound healing, skin One of the problems in wounds that are still insurmountable is delayed healing. Delayed healing occurs because of the pathological extent of inflammation. 1 It is necessary to be vigilant in order to overcome some possible complications that are caused by healing disorder. 2 Wounds are divided into two categories, namely open wounds and closed wounds. Wound healing itself is a normal biological process that occurs in the human body that goes through several phases including hemostatic, inflammation, proliferation and remodeling. 3,4 Wound healing is a complex process in which biocellular and biochemical activities occur continuously involving a series of complex reactions and interactions between cells and mediators, 5 which aim to restore the integrity of damaged tissue and will begin immediately after the occurrence of tissue damage by going through several stages of mechanism or phase. 6 Wound healing is characterized by an increase in the number of macrophages during inflammation phase. The function of macrophages in the wound healing process is to phagocytose and destroy necrotic tissue and foreign particles that enter the tissue. 7 There are two macrophage phenotypes, namely M1 and M2. 8 These two types of macrophages are distinguished by the cytokines they produce. 9 The M2 expresses cluster of differentiation 163 (CD163), 10 and produces an anti-inflammatory cytokine. 11 The M1 produces pro-inflammatory cytokines such as tumor necrosis tumor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-12 (IL-12) and interleukin-17 (IL-17). 12–16 Not only cytokines have an important role, one of the growth factors, namely fibroblast growth factor 2 (FGF-2), is also involved in the wound healing stage and can affect macrophage polarization into M2. 17 Wound management has now developed in various ways and has focused on accelerating healing by an applied material. This is intended, because for example in the case of a diabetic wound, 13,18 the wound will be difficult to heal and create delayed healing, so biomaterials are needed that are expected to accelerate the wound healing process. 19 One of the materials to accelerate wound healing is the amnion membrane. This amnion membra -Abstract Truncated-